Aldosterone Synthase Inhibitor
Dr Lim Wei Juan, Consultant Cardiologist at KPJ Johor Specialist Hospital, served as chairperson for an expert dialogue on the future of hypertension management, bringing together leading specialists to discuss uncontrolled hypertension, aldosterone dysregulation and the emerging role of aldosterone synthase inhibitors.
Held on 6 October 2026 at DoubleTree by Hilton Johor Bahru, the session, “Charting the Future: An Expert Dialogue,” explored how advances in understanding aldosterone-driven hypertension may shape the next generation of treatment strategies.
Addressing the Challenge of Uncontrolled Hypertension
Hypertension remains a major public health challenge, particularly among patients whose blood pressure remains uncontrolled despite receiving multiple antihypertensive medications. Persistent hypertension increases the risk of cardiovascular complications, including stroke, coronary artery disease, heart failure and chronic kidney disease.
The session examined the Malaysian hypertension landscape and highlighted aldosterone dysregulation as an important and potentially under-recognised contributor to difficult-to-control blood pressure.
Aldosterone, a hormone involved in sodium retention and potassium regulation, plays a significant role in blood pressure control. Excessive aldosterone activity can contribute to resistant hypertension and cardiovascular and renal injury, making the aldosterone pathway an important target for ongoing research and therapeutic development.
From Challenge to Opportunity: Aldosterone Synthase Inhibitors
The programme featured an overview of aldosterone synthase inhibition, an emerging therapeutic approach designed to reduce aldosterone production at its source.
Prof. Guangming Tan, Clinical Assistant Professor and Interventional Cardiologist at The Chinese University of Hong Kong, presented the session “From Challenge to Opportunity: Exploring New Horizons in Hypertension Through Aldosterone.”
The discussion included BaxHTN, BaxAsia and Bax24, highlighting the evolving clinical research landscape surrounding aldosterone synthase inhibitors and their potential role in hypertension management.
As research progresses, important questions remain regarding patient selection, long-term efficacy, safety, electrolyte monitoring and the place of these agents alongside established antihypertensive treatments.
An Expert Dialogue on the Future of Hypertension Treatment
As chairperson, Dr Lim Wei Juan facilitated a multidisciplinary discussion involving experts from cardiology and nephrology, encouraging an exchange of perspectives on the practical implications of emerging evidence.
The panel included:
- Prof. Guangming Tan – Clinical Assistant Professor and Interventional Cardiologist, The Chinese University of Hong Kong
- Dr. Fu Mei Sian – Consultant Nephrologist and Physician, Regency Specialist Hospital
- Assoc. Prof. Dr. Chow Yok Wai – Consultant Nephrologist, Pantai Hospital Ayer Keroh
- Dr. Lim Wei Juan – Consultant Cardiologist and Physician, KPJ Johor Specialist Hospital
The dialogue explored how clinicians might recognise patients with uncontrolled hypertension who have features suggestive of aldosterone-driven disease, how aldosterone synthase inhibitors could fit into future treatment pathways, and what additional clinical evidence is needed before their broader adoption.
The session also incorporated case-based discussion and audience questions, connecting emerging scientific developments with real-world clinical decision-making.
What Does This Mean for Patients With Difficult-to-Control Blood Pressure?
For patients whose blood pressure remains elevated despite appropriate treatment, reassessing the underlying causes is essential. This may include evaluating medication adherence, lifestyle factors, secondary hypertension and conditions such as primary aldosteronism when clinically indicated.
Although aldosterone synthase inhibitors represent an exciting area of investigation, their ultimate role will depend on robust clinical trial evidence demonstrating meaningful benefits and an acceptable safety profile.
The expert dialogue underscored the importance of evidence-based treatment, individualised patient care and continued collaboration between cardiologists, nephrologists and other healthcare professionals.
Advancing Cardiovascular Care at KPJ Johor Specialist Hospital
As Consultant Cardiologist at KPJ Johor Specialist Hospital, Dr Lim Wei Juan remains committed to clinical education, multidisciplinary collaboration and advancing cardiovascular care.
Discussions such as this provide valuable opportunities for healthcare professionals to examine emerging evidence, challenge established approaches and consider how scientific advances may translate into better outcomes for patients with hypertension and cardiovascular disease.
The future of hypertension management will depend not only on new medications, but also on identifying the right patients, understanding the underlying mechanisms of disease and applying the best available evidence to everyday clinical practice.